Anticipated $0.98 EPS for Bio-Techne Corporation (TECH) as of February, 5

Bio-Techne Corporation (NASDAQ:TECH) Corporate Logo
During Q3 2018 the big money sentiment decreased to 0.86. That’s change of 0.15, from 2018Q2’s 1.01. 30 investors sold all, 112 reduced holdings as Bio-Techne Corporation ratio dropped. 70 grew positions while 52 funds took positions. Funds hold 34.66 million shares thus 7.06% less from 2018Q2’s 37.29 million shares.
Parallax Volatility Advisers Limited Partnership owns 50 shs or 0% of their US capital. Massachusetts Serv Communication Ma invested in 677,968 shs. Da Davidson reported 1,128 shs. Ww Asset Mgmt Incorporated stated it has 2,246 shs. Pub Employees Retirement Association Of Colorado stated it has 128,125 shs or 0.16% of all its holdings. Tiaa Cref Inv Limited Liability Corp reported 114,702 shs. Atlanta Capital Mngmt L L C has 1.52% invested in Bio-Techne Corporation (NASDAQ:TECH) for 1.60 million shs. Comml Bank Of Montreal Can stated it has 13,155 shs or 0% of all its holdings. Bamco Inc New York owns 1.51 million shs or 1.28% of their US capital. Us Natl Bank De accumulated 53,756 shs. Dimensional Fund L P owns 211,911 shs. Bancorporation Of Mellon Corp holds 0.03% in Bio-Techne Corporation (NASDAQ:TECH) or 510,911 shs. Baystate Wealth Management Limited Liability holds 119 shs. Guggenheim Cap Ltd Llc has invested 0.04% in Bio-Techne Corporation (NASDAQ:TECH). Gsa Cap Prtnrs Limited Liability Partnership accumulated 9,423 shs or 0.11% of the stock.

Bio-Techne Corporation had 2 sales and 0 insider buys since August 23, 2018. This’s net activity of $2.82 million. BAUMGARTNER ROBERT V also sold $942,334 worth of Bio-Techne Corporation (NASDAQ:TECH) shs.

Bio-Techne Corporation (NASDAQ:TECH)’s earnings report is anticipated by WallStreet on February, 5, according to RTT. The EPS diference is $0.07 or 7.69 % up from last years number. Previous year: $0.91; Analysts forcast: $0.98. If the current EPS of $0.98 is accurate, TECH’s profit could be $37.01 million. 25.64 % EPS growth is what Wall Street’s forecasts after $0.78 reported EPS last quarter. Ticker’s shares touched $157.01 during the last trading session after 0.48% change.Currently Bio-Techne Corporation is uptrending after 20.74% change in last January 14, 2018. TECH has also 165,286 shares volume. TECH outperformed the S&P 500 by 20.74%.

Bio-Techne Corporation (NASDAQ:TECH) Ratings Coverage

Total analysts of 4 have positions in Bio-Techne (NASDAQ:TECH) as follows: 2 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 50%. Since August 9, 2018 according to StockzIntelligence Inc Bio-Techne has 4 analyst reports. On Wednesday, October 31 Craig Hallum downgraded the shares of TECH in report to “Hold” rating. On Thursday, August 9 the rating was maintained by Citigroup with “Buy”. On Tuesday, October 2 the firm has “Buy” rating given by Argus Research.

Bio-Techne Corporation, together with its subsidiaries, develops, makes, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide.The firm is valued at $5.93 billion. It operates through three divisions: Biotechnology, Protein Platforms, and Diagnostics.47.16 is the P/E ratio. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.

Bio-Techne Corporation (NASDAQ:TECH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.